10x Genomics reported second quarter 2026 financial results with revenue of $151.0 million, a decline from $172.9 million in the prior year period. Excluding non-recurring patent litigation settlement revenues of $1.6 million and $27.3 million respectively, organic revenue increased 3%. The company reported an operating loss of $19.6 million compared to operating income of $30.1 million previously, driven by a lower gain on settlement. Full-year 2026 revenue guidance was raised to $610–$630 million from the previous range of $600–$625 million. The company also announced the acquisition of Proteintech Genomics and new research collaborations with Cleveland Clinic and Lausanne University Hospital. Cash and marketable securities stood at $552.0 million as of June 30, 2026. 10x Genomics operates in the life science technology industry, developing integrated instruments, consumables, and software for single cell and spatial biology research.

10x Genomics, Inc. reported the results of its annual meeting of stockholders held on June 4, 2026. Stockholders approved the election of three Class I directors, ratified the appointment of Ernst & Young LLP as the independent auditor, and approved the executive compensation of named executive officers on an advisory basis.